Skip to main content
Clinical Trials/NCT06603090
NCT06603090
Completed
Not Applicable

Text4Vax: Understanding the Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-2025 Season

Columbia University4 sites in 1 country66,147 target enrollmentOctober 2, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Influenza
Sponsor
Columbia University
Enrollment
66147
Locations
4
Primary Endpoint
Timeliness of influenza vaccination
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.

Detailed Description

The study is to be conducted over the 1st season (September 2024-April 2025) as an effectiveness trial and the 2nd (September 2025-April 2026) as a replication study. This protocol covers the first season. Parents of eligible children who are 6 month-17 year-old who are due for both a COVID-19 and influenza vaccine will be sent text messages. Within each practice site, parents of eligible children will be randomized to receive either: 1) combined COVID-19 and influenza vaccine text message reminders, 2) COVID-19 reminders alone, 3) influenza reminders alone, or 4) no reminders (usual care). Randomization is to be stratified by practice site, age group and prior year's COVID-19/influenza vaccine history. Messages will be sent centrally and managed by the research team.

Registry
clinicaltrials.gov
Start Date
October 2, 2024
End Date
April 30, 2025
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Melissa Stockwell

Professor of Pediatrics; Professor of Population and Family Health

Columbia University

Eligibility Criteria

Inclusion Criteria

  • Child that:
  • is 6 months-17 year-old children
  • due for both a COVID-19 and influenza vaccine
  • Receives care at study site
  • Language listed in electronic health record is English or Spanish
  • Has not opted out of text messages from practice

Exclusion Criteria

  • Has opted out of text messages from practice
  • Language listed in electronic health record is not English or Spanish

Outcomes

Primary Outcomes

Timeliness of influenza vaccination

Time Frame: Up to December 31 each year, up to ~90 days

Days from study start to influenza vaccine up to December 31 each year

Timeliness of COVID-19 vaccination

Time Frame: Up to December 31 each year, up to ~90 days

Days from study start to COVID-19 vaccine up to December 31 each year

Secondary Outcomes

  • Percentage of Participants Who Received Influenza Vaccine by December 31 Each Year(~3 months)
  • Percentage of Participants Who Received COVID-19 Vaccine by December 31 Each Year(~3 months)
  • Percentage of Participants Who Received Influenza Vaccine by April 30 Each Year(~7 months)
  • Percentage of Participants Who Received COVID-19 Vaccine by April 30 Each Year(~7 months)
  • Timeliness of influenza vaccination(Up to April 30 each year, up to ~210 days)
  • Timeliness of COVID-19 vaccination(Up to April 30 each year, up to ~210 days)

Study Sites (4)

Loading locations...

Similar Trials